Schizophrenia is known to be accompanied with increased cardiovascular mortality, which causes reduced life expectancy.
Aim:
The aim of the current study was to investigate if atherogenic index of plasma (AIP) could be a good marker in assessing cardiovascular disease (CVD) risk in patients with schizophrenia.
Methods:
Patients with schizophrenia (n = 328) and healthy controls (n = 141) were recruited. Schizophrenia patients were evaluated according to the presence of antipsychotic (AP) drug use as AP(+)Sch group and AP(−)Sch group. Atherogenic indices, such as AIP, Castelli’s risk index-I (CRI-I), Castelli’s risk index-II (CRI-II), and atherogenic coefficient (AC), were calculated according to the laboratory examination of serum lipid parameters.
Results:
According to the comparison of serum lipid levels, triglyceride (TG) levels were found to be highest and high-density lipoprotein–cholesterol levels were lowest in AP(+)Sch group than AP(−)Sch group and control group (CG) (p < 0.001). AIP, CRI-I, and CRI-II scores were found to be significantly higher in AP(+)Sch group than AP(−)Sch group, and in AP(−)Sch than healthy controls (p < 0.001). Mean AC scores were higher in AP(+)Sch group than both AP(−)Sch and CG and were similar in AP(−)Sch and control subjects (p < 0.001). According to the correlation analysis, AIP scores were positively correlated with duration of disease (r = 0.235; p = 0.002) and age (r = 0.226; p = 0.003) in AP(+)Sch group but not in drug-free subjects. In all groups, atherogenic indices of CRI-I, CRI-II, and AC scores were found to be positively correlated with AIP scores (p < 0.001).
Conclusion:
Our results suggest that AIP is an easily calculable and reliable marker for determining the CVD risk in both drug-free schizophrenia patients and patients under AP treatment.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists. (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27: 596–601.
2.
AndreassenOADjurovicSThompsonWK, et al. (2013) Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet92: 197–209.
3.
BaliarsinghSSharmaNMukherjeeR (2013) Serum uric acid: Marker for atherosclerosis as it is positively associated with “atherogenic index of plasma”. Arch Physiol Biochem119: 27–31.
4.
BearyMHodgsonRWildgustHJ (2012) A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: Clinical and research implications. J Psychopharmacol26: 52–61.
5.
BhardwajSBhattacharjeeJBhatnagarM, et al. (2013) Atherogenic index of plasma, Castelli risk index and atherogenic coefficient – New parameters in assessing cardiovascular risk. Int J Pharm Biol Sci3: 359–364.
6.
BirkenaesABBirkelandKIEnghJA, et al. (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol28: 132–137.
7.
BosMBde VriesJHFeskensEJ, et al. (2010) Effect of a high monounsaturated fatty acids diet and a Mediterranean diet on serum lipids and insulin sensitivity in adults with mild abdominal obesity. Nutr Metab Cardiovasc Dis20: 591–598.
8.
CarneyRCotterJBradshawT, et al. (2016) Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. Schizophr Res170: 290–300.
9.
ChenSBroqueres-YouDYangG, et al. (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res210: 825–829.
10.
ChungKHChenPHKuoCJ, et al. (2018) Risk factors for early mortality in patients with schizophrenia. Psychiatry Res267: 7–11.
11.
CitromeL (2005) Metabolic syndrome and cardiovascular disease. J Psychopharmacol19: 84–93.
12.
CooperSJReynoldsGPBarnesT, et al. (2016) BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol30: 717–748.
13.
CordesJBechdolfAEngelkeC, et al. (2017) Prevalence of metabolic syndrome in female and male patients at risk of psychosis. Schizophr Res181: 38–42.
14.
CorrellCUFredericksonAMKaneJM, et al. (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry67: 575–583.
15.
CorrellCUFredericksonAMKaneJM, et al. (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord10: 788–797.
16.
CorrellCURobinsonDGSchoolerNR, et al. (2014) Cardiometabolic risk in first episode schizophrenia-spectrum disorder patients: Baseline results from the RAISE-ETP study. JAMA Psychiatry71: 1350–1363.
17.
DaumitGLGoldbergRWAnthonyC, et al. (2005) Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis193: 641–646.
18.
DavisCRBryanJHodgsonJM, et al. (2017) A Mediterranean diet reduces F2-Isoprostanes and triglycerides among older Australian men and women after 6 months. J Nutr147: 1348–1355.
19.
DillonDGGurdasaniDRihaJ, et al. (2013) Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: A systematic review and meta-analysis. Int J Epidemiol42: 1754–1771.
20.
DipasqualeSParianteCMDazzanP, et al. (2013) The dietary pattern of patients with schizophrenia: A systematic review. J Psychiatry Res47: 197–207.
21.
DobiasovaMFrohlichJ (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem34: 583–588.
22.
EckelRHGrundySMZimmetPZ (2005) The metabolic syndrome. Lancet365: 1415–1428.
23.
Enez DarcinAYalcin CavusSDilbazN, et al. (2015) Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings. Schizophr Res166: 201–206.
24.
FleischhackerWWSiuCOBodénR, et al. (2013) Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol16: 987–995.
25.
GalletlyCAFoleyDLWaterreusA, et al. (2012) Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. Aust N Z J Psychiatry46: 753–761.
26.
GoffDCJrLloyd-JonesDMBennettG, et al. (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation129: 49–73.
27.
GoffDCJrSullivanLMMcEvoyJP, et al. (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res80: 45–53.
28.
GoncalvesPAraujoJRMartelF (2015) Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. Eur Neuropsychopharmacol25: 1–16.
29.
HendersonDCCaglieroEGrayC, et al. (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry157: 975–981.
30.
JassimGSkredeSVázquezMJ, et al. (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl)219: 783–794.
31.
KhazaálMS (2013) Atherogenic Index of Plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med6: 1506–1513.
32.
KolevaDIAndreeva-GatevaPAOrbetzovaMM, et al. (2015) Atherogenic index of plasma, Castelli risk indexes and leptin/adiponectin ratio in women with metabolic syndrome. Int J Pharm Med Res3: 12–18.
33.
Kris-EthertonPMBinkoskiAEZhaoG, et al. (2002) Dietary fat: Assessing the evidence in support of a moderate-fat diet; the benchmark based on lipoprotein metabolism. Proc Nutr Soc61: 287–289.
34.
LallyJGallagherABainbridgeE, et al. (2013) Increases in triglyceride levels are associated with clinical response to clozapine treatment. J Psychopharmacol27: 401–403.
35.
LaursenTMMunk-OlsenTVestergaardM (2012) Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry25: 83–88.
36.
LaursenTMNordentoftMMortensenPB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol10: 425–448.
37.
LawrenceDKiselyS (2010) Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol24: 61–68.
38.
LorenzattiAJTothPP (2020) New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol15: 1–9.
39.
McEvoyJPMeyerJMGoffDC, et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res80: 19–32.
40.
McGintyEEBallerJAzrinST, et al. (2015) Quality of medical care for persons with serious mental illness: A comprehensive review. Schizophr Res165: 227–235.
41.
MackinPBishopDWatkinsonH, et al. (2007) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry191: 23–29.
42.
MisiakBŁaczmańskiŁSłokaNK, et al. (2016) Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism. Psychiatry Res238: 60–67.
43.
MitchellAJVancompfortDSweersK, et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – A systematic review and meta-analysis. Schizophr Bull39: 306–318.
44.
Moussavi JavardiMSMadaniZMovahediA, et al. (2020) The correlation between dietary fat quality indices and lipid profile with Atherogenic index of plasma in obese and non-obese volunteers: A cross-sectional descriptive-analytic case-control study. Lipids Health Dis19: 213.
45.
MusilRObermeierMRussP, et al. (2015) Weight gain and antipsychotics: A drug safety review. Expert Opin Drug Saf14: 73–96.
NasrallahHAMeyerJMGoffDC, et al. (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res86: 15–22.
48.
National Cholesterol Education Program (NCEP), Expert Panel on Detection, Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation106: 3143–3421.
49.
NimmanapalliHDKasiADDevapatlaPK, et al. (2016) Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus. Int J Res Med Sci4: 2863–2869.
50.
NiroumandSKhajedalueeMKhadem-RezaiyanM, et al. (2015) Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran29: 240.
51.
NordentoftMWahlbeckKHällgrenJ, et al. (2013) Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One8: e55176.
52.
OnatA (2004) Lipids, lipoproteins and apolipoproteins among Turks, and impact on coronary heart disease. Anadolu Kardiyol Derg4: 236–245.
53.
OnatACanGKayaH, et al. (2010) “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol4: 89–98.
54.
ProtopopovaDMasopustJMalyR, et al. (2012) The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders. Psychiatr Danub24: 307–313.
55.
RaderDJHovinghGK (2014) HDL and cardiovascular disease. Lancet384: 618–625.
56.
RanjidPMGuntukuGPothineniRB (2015) New atherogenic indices: Assessment of cardiovascular risk in postmenopausal dyslipidemia. Asian J Med Sci6: 25–32.
57.
SenguptaSParrilla-EscobarMAKlinkR, et al. (2008) Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?Schizophr Res102: 329–336.
58.
SimopoulosAP (2002) The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother56: 365–379.
59.
SošskaVJarkovskýJRavčukováB, et al. (2012) The logarithm of the triglyceride/HDL-cholesterol ratio is related to the history of cardiovascular disease in patients with familial hypercholesterolemia. Clin Biochem45: 96–100.
60.
SteinRFerrariFScolariF (2019) Genetics, dyslipidemia, and cardiovascular disease: New insights. Curr Cardiol Rep21: 68.
61.
TothPPBarterPJRosensonRS, et al. (2013) High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol7: 484–525.
62.
VancampfortDWampersMMitchellAJ, et al. (2013) A meta-analysis of cardiometabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry12: 240–250.
63.
WuXHuangZWuR, et al. (2013) The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res150: 157–162.
64.
YoungSLTaylorMLawrieSM (2015) “First do no harm”: A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol29: 353–362.
65.
ZhaiDLangYFengY, et al. (2017) Early onset of cardiometabolic risk factor profiles in drug naive adolescents and young adults with first-episode schizophrenia. Schizophr Res190: 60–62.
66.
ZhangXZhangXLiX, et al. (2019) Association of metabolic syndrome with atherogenic index of plasma in an urban Chinese population: A 15-year prospective study. Nutr Metab Cardiovasc Dis29: 1214–1219.
67.
ZhangZJYaoZJLiuW, et al. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry184: 58–62.
